Mefenamic Acid: Fenamate NSAID, Dysmenorrhea, Short-Course Dosing and Safety

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information.

Overview and chemical classification

Mefenamic acid is an anthranilic acid-derived NSAID of the fenamate family, correctly named 2-[(2,3-dimethylphenyl)amino]benzoic acid. It reversibly inhibits cyclooxygenase COX-1 and COX-2, suppressing prostaglandin synthesis. The original monograph’s chemical name was inaccurate, and it should not be described as a clinically COX-2-selective agent [1,2].

Mechanism and clinical benefits

Reduced prostaglandin synthesis decreases peripheral nociceptor sensitization and uterine prostaglandin-mediated contractions, explaining analgesia in primary dysmenorrhea. Mefenamic acid does not treat the underlying causes of secondary dysmenorrhea, and persistent or atypical menstrual pain warrants evaluation. Unlike hormonal therapies, its effect is symptomatic rather than cycle-modifying [1].

Indications and labeled course limits

US labeling permits treatment of mild-to-moderate pain in patients aged 14 years or older for a maximum of seven days, and primary dysmenorrhea. A common labeled regimen is 500 mg orally initially, then 250 mg every six hours as needed; primary dysmenorrhea generally requires only two to three days beginning with bleeding and symptoms. These are label examples, not individualized prescribing instructions; different countries have different products and instructions [2].

Pharmacokinetics

Mefenamic acid is absorbed orally, extensively protein bound and metabolized mainly through hepatic CYP2C9-dependent pathways with urinary and fecal excretion of metabolites. The plasma elimination half-life is relatively short, so dosing frequency reflects both pharmacokinetics and clinical response. Kidney impairment, dehydration and liver disease can alter tolerability and risk [1,2].

Boxed NSAID safety warning

Like other systemic nonaspirin NSAIDs, mefenamic acid increases risk of serious cardiovascular thrombotic events and potentially fatal GI ulceration, bleeding or perforation; events may occur without warning. It is contraindicated around coronary artery bypass graft surgery and after aspirin/NSAID-induced serious hypersensitivity. Avoid in advanced kidney impairment and assess prior GI bleeding, cardiovascular risk, dehydration and concurrent anticoagulants [2].

Interactions, pregnancy and counseling

Concurrent NSAIDs, aspirin, glucocorticoids, anticoagulants or SSRIs may increase GI/bleeding risk. ACE inhibitors/ARBs and diuretics can combine with NSAIDs to cause AKI, especially in volume depletion. NSAIDs may cause fetal renal dysfunction/oligohydramnios at about 20 weeks or later and premature ductal closure at about 30 weeks or later; avoid or restrict according to gestation and clinician guidance. Use the lowest effective dose for the shortest period [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Mefenamic acid capsules: prescribing information, updated January 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *